MAGEA3 and neoplasm: A phase 2 clinical study (NCT00086866) revealed that AS15 combined with melanoma antigen family A, 3 (MAGE‐A3) tumor antigen induced strong clinical activity (robust MAGE‐A3 specific antibody and T cell immune response) in patients with melanoma,[138] thus phase 3 studies of MAGE‐A3+AS15 therapeutic vaccines were initiated in patients with surgically resected melanoma (NCT00796445) and non‐small‐cell lung cancer (NSCLC) (NCT00480025).